



Identifying novel therapies for the prevention and treatment of gender specific oncology

Tuesday 7th July 2009, The Royal Society, London

The oncology market has grown considerably in recent years, driven by the onset of targeted therapy and the high level of unmet needs for effective treatment. The increase in new product introductions that began in 1997 has seen the size of the oncology market more than double in the past 5 years and the majority of this growth can be attributed to targeted therapies. This event will bring together senior representatives to address these issues via LTN's unique network of academics and industry experts. This event will:

- **HIGHLIGHT** the benefits of novel therapeutic approaches for the prevention of cervical cancer
- **ASSESS** how the early detection of breast cancer affects patient prognosis
- **UNDERSTAND** the challenges in diagnosis and treatment of male specific cancers
- **CREATE** opportunities for collaborative research and research partnerships between industry and academia

10:00 Registration with tea and coffee

10:15 Introduction to the aims and objectives of LTN and the EMT Group

Chair: Dr Matthew Killeen, Technology Analyst, Life Sciences, London Technology Network

10:25 Developing and implementing vaccines for the prevention of cervical cancer

- ◆ Ensuring efficacy, effectiveness, safety and administration of vaccines
- ◆ Looking at recent developments in clinical trials
- ◆ Establishing where new technology is required, and the potential for collaboration between industry and academia

10:40 Investigating genetic predisposition to breast cancers through risk assessment

- ◆ The Prospective Study of Outcomes in Sporadic versus Hereditary (POSH) Breast Cancer
- ◆ Developing pathology based tests to detect high risk BRCA1 and BRCA2 gene carriers
- ◆ Prognosis in breast cancer associated with commonly inherited genetic variants

Diana Eccles, Professor of Cancer Genetics, School of Medicine, University of Southampton

10:55 Addressing recent developments in the early prevention of testicular cancer

- ◆ Considering novel emerging technologies and new therapeutic approaches
- ◆ Highlighting the challenges of diagnosis and treatment
- ◆ Using case studies to highlight how industry and academia can work together

Dr Tom Powles, Senior Lecturer in Urology Cancer & Honorary Consultant in Medical Oncology, Centre for Experimental Cancer Medicine, Barts & The London School of Medicine & Dentistry

11:10 Considering new perspectives in the treatment of prostate cancer

- ◆ Understanding the use of prostate-specific antigen (PSA) in prostate cancer follow-up and secondary treatment
- ◆ Exploring and developing targeted cancer therapies for treating patients
- ◆ Delivering promising vaccine therapies to prolong the lives of patients while maximising the quality of life
- ◆ Successfully designing studies for clinical trials

Professor Donald Newling, Senior Clinical Research Physician, Urology, AstraZeneca

11:25 Question and answer session from the audience with the speaker panel

12:00 Networking lunch: opportunity to view posters showcasing the latest research and developments in the field of oncology

13:00 End of seminar

LTN's Emerging Medical Technologies Group

A special interest group bringing together the best biomedical experts from industry, academia and government, across the Greater South-East, to stimulate knowledge exchange

The Group produces regular networking events on emerging medical technologies which have discussed a range of topics, attracting over 800 representatives from across the public and private sectors. Membership is free and includes:

- Priority invitations to the group's seminars, workshops and networking events
- Regular e-newsletters, with the latest sector news and listings of UK and international events
- Access to Enterprise Europe Network – a multi-partner consortium spanning 40 countries across Europe

If you would like further information or would like to become a member of this group please contact Natalie Tamiollo, Special Interest Group Manager at n.tamiollo@LTNetwork.org or on 0870 730 8683

Registration & Payment:

Commercial - £80.00 (+ VAT = £12.00) - £92.00

SME - £40.00 (+ VAT = £6.00) - £46.00 Please note that the SME (Small and Medium Enterprises) rate is available to companies with up to 250 employees

Academic - Free

All payments must be received prior to the conference and should be made within 14 days of receiving a provisional place. Attendance will be confirmed upon receipt of payment. Prices include all refreshments and delegate documentation. All LTN events are by INVITATION ONLY to ensure that the quality of interaction is maintained. To apply for an invitation, and to find out about different payment methods, please email **Emma Graham** at e.graham@LTNetwork.org. **Cancellations must be made at least 7 days prior to the event.**

HOW TO GET THERE

The event will take place at **The Royal Society**, 6-9 Carlton House Terrace, London, SW1Y 5AG. For details on the venue please call 020 7451 2500 or visit: www.royalsociety.org



Train

London Charing Cross and London Victoria are the nearest main line railway stations

Underground

The nearest underground stations are Charing Cross (Bakerloo and Northern lines) and Piccadilly Circus (Bakerloo and Piccadilly lines)

Car

Please note that there are no car parking facilities at the society. If travelling by car there are many metered bays and car parks within a short walk